<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00315627</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0205</org_study_id>
    <nct_id>NCT00315627</nct_id>
  </id_info>
  <brief_title>Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation</brief_title>
  <official_title>Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rodolfo Alejandro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:&#xD;
&#xD;
        1. To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes&#xD;
           mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor&#xD;
           free immunosuppression.&#xD;
&#xD;
        2. To assess the long-term function of successful islet transplants in patients with type 1&#xD;
           diabetes mellitus utilizing islets that have undergone a period of culture.&#xD;
&#xD;
        3. To determine whether the natural history of the microvascular, macrovascular, and&#xD;
           neuropathic complications are altered following the successful transplantation of&#xD;
           islets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN:&#xD;
&#xD;
      The initial proposal submitted to the JDRFI was to compare 3 different groups of patients&#xD;
      receiving islet cell transplants utilizing steroid-free, calcineurin-free protocols. The 3&#xD;
      groups were as follows:&#xD;
&#xD;
        1. Zenapax, Rapamycin &amp; MMF&#xD;
&#xD;
        2. Campath, Rapamycin &amp; MMF, and&#xD;
&#xD;
        3. Thymoglobulin, Rapamycin &amp; MMF.&#xD;
&#xD;
      The grant was awarded in December 2003, however the recommendations were to focus on a single&#xD;
      group (group 3 or 4) in order to determine the relative efficacy and toxicity of a new&#xD;
      immunosuppressive drug combination. We elected to perform the group utilizing Campath, since&#xD;
      we have a similar protocol utilizing the same immunosuppressive regimen with the addition of&#xD;
      CD34+ enriched donor bone marrow cells (2000/0024). The results of this trial utilizing a&#xD;
      steroid-free/calcineurin-free protocol will be compared with the standard &quot;Edmonton Protocol&quot;&#xD;
      (2000/0196), which we are currently conducting (14 patients have been transplanted). In&#xD;
      addition, the results will be compared with those in 2000/0024.&#xD;
&#xD;
      Protocol 2000/0024 (utilizing the same immunosuppressive regimen; Campath, Rapamycin,&#xD;
      Tacrolimus-switched to MMF at 3 months) is being followed by a DSMB established at the NIH.&#xD;
&#xD;
      We propose to evaluate 12 patients with steroid free, long term calcineurin inhibitor free&#xD;
      immunosuppression regimens which can be directly compared to our historical group of patients&#xD;
      who underwent the Miami version of the Edmonton protocol (Islet Cell Transplantation Alone in&#xD;
      Patients with Type 1 Diabetes Mellitus: Steroid-Free Immunosuppression - Protocol # 2000/196)&#xD;
      and with the concurrent tolerogenic protocol (Islet Cell Transplantation Alone and CD34+&#xD;
      Enriched Donor Bone Marrow Cell Infusion in Patients with Type 1 Diabetes Mellitus; Steroid&#xD;
      Free Regimen - Protocol # 2000/0024) which uses the same immunosuppressive regimen combined&#xD;
      with CD34+ stem cell enriched donor bone marrow infusions.&#xD;
&#xD;
      The regimen will consist of Campath 1-H induction, maintenance immunosuppression with&#xD;
      sirolimus and tacrolimus for 3 months with subsequent introduction of mycophenolate mofetil&#xD;
      (MMF) and removal of tacrolimus completely and TNF-alpha inhibition (etanercept) in the&#xD;
      peri-transplant period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects at 1 year with HbA1c &lt; 6.5% and absence of severe hypoglycemia</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Islet Allograft Function</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with basal C-peptide greater than 0.5 ng/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Metabolic Control as Evidenced by Hemoglobin A1c &lt; 6.5%</measure>
    <time_frame>1 year</time_frame>
    <description>Number of subjects with a hemoglobin A1c &lt; 6.5% at 1year after islet transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination of Severe Hypoglycemia</measure>
    <time_frame>1 year</time_frame>
    <description>The number of subjects with severe hypoglycemia after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restoration of Hypoglycemia Awareness 1 Year After Transplantation</measure>
    <time_frame>1 year</time_frame>
    <description>The number of subjects with restoration of hypoglycemia awareness 1 year after islet transplantation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>islet transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Islet transplantation</intervention_name>
    <description>Islet transplantation</description>
    <arm_group_label>islet transplantation</arm_group_label>
    <other_name>islet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Potential candidates must have type 1 diabetes mellitus and fulfill one or more of the&#xD;
        following:&#xD;
&#xD;
          1. Manifest signs and symptoms that are severe enough to be incapacitating.&#xD;
             Incapacitating signs and symptoms include hypoglycemic episodes requiring assistance&#xD;
             by others and hypoglycemia unawareness (the inability to recognize low blood glucoses;&#xD;
             glucoses &lt; 54 mg/dl). These patients are at high risk for involvement in accidents&#xD;
             (they can lose consciousness or act irrationally), thus causing harm to themselves&#xD;
             and/or others.&#xD;
&#xD;
          2. Patients with poor diabetes control (HbA1c &gt; 8.0% but &lt; 12%), despite intensive&#xD;
             insulin therapy, as defined by: self monitoring of blood glucose ≥ 4 times/day,&#xD;
             multiple insulin injections (≥ 3/day) or insulin pump, and close monitoring of blood&#xD;
             glucose control by an endocrinologist. These patients can experience acute, rapid&#xD;
             hyperglycemia secondary to several stress factors, that can lead to dehydration,&#xD;
             disorientation, and in some instances, ketoacidosis.&#xD;
&#xD;
          3. Progressive diabetic complications. These patients with chronically poor glycemic&#xD;
             control are at higher risk for the development of a wide variety of complications&#xD;
             (retinopathy, neuropathy, nephropathy, and cardiovascular disease) associated with&#xD;
             diabetes.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Potential candidates will be excluded as per the following criteria:&#xD;
&#xD;
          1. Age &lt; 18 or &gt; 65 years&#xD;
&#xD;
          2. Duration of diabetes &lt; 5 years&#xD;
&#xD;
          3. Do not have a physician that is monitoring diabetes for &gt; 6 months&#xD;
&#xD;
          4. Body mass index &gt; 26&#xD;
&#xD;
          5. Weight &gt; 80 kg&#xD;
&#xD;
          6. Insulin requirement &gt; 1.0 u/kg/d&#xD;
&#xD;
          7. HbA1c &gt; 12%&#xD;
&#xD;
          8. Stimulated or basal C-peptide &gt; 0.3 ng/ml&#xD;
&#xD;
          9. Corrected creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
         10. Serum creatinine consistently above 1.6 mg/dl&#xD;
&#xD;
         11. Macroalbuminuria (&gt; 300 mg/24 hours)&#xD;
&#xD;
         12. Anemia (hemoglobin &lt; 12.0 g/dl for males; &lt; 11 g/dl for females)&#xD;
&#xD;
         13. Hyperlipidemia (fasting low-density lipoprotein [LDL] cholesterol &gt; 130 mg/dl and/or&#xD;
             fasting triglycerides &gt; 200 mg/dl)&#xD;
&#xD;
         14. Abnormal liver function tests (consistently &gt; 1.5 x normal range)&#xD;
&#xD;
         15. Serological evidence of HIV, HBsAg and/or HBcAb, HBsAb without history of vaccination,&#xD;
             human t cell lymphotropic virus 1 (HTLV-1), or hepatitis C virus (HCV)&#xD;
&#xD;
         16. Negative serology for Epstein-Barr virus (EBV) or evidence of acute or chronic&#xD;
             infection (IgM ≥ IgG)&#xD;
&#xD;
         17. Lack of updated immunizations per current Centers for Disease Control (CDC) guidelines&#xD;
             (including lack of immunization against hepatitis B, pneumococcus and influenza -&#xD;
             during season)&#xD;
&#xD;
         18. Presence of panel reactive antibodies &gt; 20%&#xD;
&#xD;
         19. Prostate-specific antigen (PSA) &gt; 4 ng/ml unless malignancy is ruled out&#xD;
&#xD;
         20. Positive tuberculin test (unless proof of adequate treatment for latent tuberculosis&#xD;
             can be provided)&#xD;
&#xD;
         21. X-ray evidence of pulmonary infection or other significant pathology&#xD;
&#xD;
         22. Gall stones and/or portal hypertension and/or hemangioma on liver ultrasound&#xD;
&#xD;
         23. Abnormal abdominal or pelvic ultrasound (evidence of masses that are considered&#xD;
             suspicious for malignancy or adenopathy)&#xD;
&#xD;
         24. Active peptic ulcer disease&#xD;
&#xD;
         25. Active infections&#xD;
&#xD;
         26. Unstable cardiovascular status (including positive stress echocardiography if age &gt;&#xD;
             35)&#xD;
&#xD;
         27. Untreated or unstable proliferative diabetic retinopathy&#xD;
&#xD;
         28. Previous/concurrent organ transplantation (except for failed islet cell or pancreas&#xD;
             transplantation)&#xD;
&#xD;
         29. Malignancy or previous malignancy&#xD;
&#xD;
         30. Any medical condition requiring chronic use of steroids&#xD;
&#xD;
         31. Active alcohol or substance abuse; smoking in the last 6 months.&#xD;
&#xD;
         32. Sexually active females who are not:&#xD;
&#xD;
               -  post-menopausal,&#xD;
&#xD;
               -  surgically sterile, or&#xD;
&#xD;
               -  not using an acceptable method of contraception (oral contraceptives, Norplant,&#xD;
                  Depo-Provera, and barrier devices with spermicide are acceptable; condoms used&#xD;
                  alone are not acceptable)&#xD;
&#xD;
         33. Positive pregnancy test or intent for future pregnancy, or male subject's intent to&#xD;
             procreate&#xD;
&#xD;
         34. Any condition or any circumstances that make it unsafe to undergo an islet cell&#xD;
             transplant&#xD;
&#xD;
         35. Psychogenically unable to comply&#xD;
&#xD;
         36. Failed psychological evaluation&#xD;
&#xD;
         37. Persistent leukopenia (white blood cell count &lt; 3,000/uL on more than 3 occasions)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodolfo Alejandro, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Diabetes Research Institute - University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Diabetes Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.diabetesresearch.org</url>
    <description>Diabetes Research Institute web site</description>
  </link>
  <results_reference>
    <citation>Froud T, Baidal DA, Faradji R, Cure P, Mineo D, Selvaggi G, Kenyon NS, Ricordi C, Alejandro R. Islet transplantation with alemtuzumab induction and calcineurin-free maintenance immunosuppression results in improved short- and long-term outcomes. Transplantation. 2008 Dec 27;86(12):1695-701. doi: 10.1097/TP.0b013e31819025e5.</citation>
    <PMID>19104407</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>April 14, 2006</study_first_submitted>
  <study_first_submitted_qc>April 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2006</study_first_posted>
  <results_first_submitted>December 19, 2016</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 25, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Rodolfo Alejandro</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Islet Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Islet Transplantation</title>
          <description>Single arm study. Subjects with Type 1 Diabetes, severe hypoglycemia and hypoglycemia unawareness received intrahepatic islet transplantation (1 or 2 infusions) under alemtuzumab induction and rapamycin + MMF maintenance immunosuppression.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Islet Transplantation</title>
          <description>Islet transplantation: Islet transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia</title>
        <description>Number of subjects at 1 year with HbA1c &lt; 6.5% and absence of severe hypoglycemia</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Single arm study. Subjects with Type 1 Diabetes, severe hypoglycemia and hypoglycemia unawareness received intrahepatic islet transplantation (1 or 2 infusions) under alemtuzumab induction and rapamycin + MMF maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Measurement of Glycemic Control by HbA1c and Prevention of Severe Hypoglycemia</title>
          <description>Number of subjects at 1 year with HbA1c &lt; 6.5% and absence of severe hypoglycemia</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Islet Allograft Function</title>
        <description>Number of subjects with basal C-peptide greater than 0.5 ng/ml</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.</description>
          </group>
        </group_list>
        <measure>
          <title>Islet Allograft Function</title>
          <description>Number of subjects with basal C-peptide greater than 0.5 ng/ml</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Metabolic Control as Evidenced by Hemoglobin A1c &lt; 6.5%</title>
        <description>Number of subjects with a hemoglobin A1c &lt; 6.5% at 1year after islet transplantation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Metabolic Control as Evidenced by Hemoglobin A1c &lt; 6.5%</title>
          <description>Number of subjects with a hemoglobin A1c &lt; 6.5% at 1year after islet transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Elimination of Severe Hypoglycemia</title>
        <description>The number of subjects with severe hypoglycemia after transplantation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Islet Alone Transplantation under Alentuzumab (Campath1H) induction.&#xD;
Islet transplantation: Islet transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Elimination of Severe Hypoglycemia</title>
          <description>The number of subjects with severe hypoglycemia after transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Restoration of Hypoglycemia Awareness 1 Year After Transplantation</title>
        <description>The number of subjects with restoration of hypoglycemia awareness 1 year after islet transplantation</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Islet Transplantation</title>
            <description>Single arm study. Subjects with Type 1 Diabetes, severe hypoglycemia and hypoglycemia unawareness received intrahepatic islet transplantation (1 or 2 infusions) under alemtuzumab induction and rapamycin + MMF maintenance immunosuppression.</description>
          </group>
        </group_list>
        <measure>
          <title>Restoration of Hypoglycemia Awareness 1 Year After Transplantation</title>
          <description>The number of subjects with restoration of hypoglycemia awareness 1 year after islet transplantation</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Islet Transplantation</title>
          <description>Islet transplantation alone under alentuzumab (Campath1H) induction.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <description>lymphopenia secondary to t-cell depletion with alentuzumab (Campath1H)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <description>chest pain, back pain, abdominal pain with nausea and vomiting after administration of IV iron (Ferrlecit; sodium ferric gluconate) for anemia.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Capsular opacity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gallblader polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pulpitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Right foot injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Muscle cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Toe sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremors</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headaches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Memory deficit</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Overt Proteinuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Yeast infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Uterine fibroids</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hot Flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abnormal Papsmear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rinorrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hair loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Displastic Nevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Acne/Folliculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombophlebitis Right arm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Rodolfo Alejandro</name_or_title>
      <organization>University of Miami Miller School of Medicine</organization>
      <phone>305 243-5324</phone>
      <email>ralejand@med.miami.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

